SE9803710L - Användning av vissa substanser för behandling av nervrotsskador - Google Patents

Användning av vissa substanser för behandling av nervrotsskador

Info

Publication number
SE9803710L
SE9803710L SE9803710A SE9803710A SE9803710L SE 9803710 L SE9803710 L SE 9803710L SE 9803710 A SE9803710 A SE 9803710A SE 9803710 A SE9803710 A SE 9803710A SE 9803710 L SE9803710 L SE 9803710L
Authority
SE
Sweden
Prior art keywords
treatment
nerve root
certain substances
root damage
tnf
Prior art date
Application number
SE9803710A
Other languages
English (en)
Swedish (sv)
Other versions
SE9803710D0 (sv
Inventor
Kjell Olmarker
Bjoern Rydevik
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9803710(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9803276A external-priority patent/SE9803276D0/xx
Application filed by A & Science Invest Ab filed Critical A & Science Invest Ab
Priority to SE9803710A priority Critical patent/SE9803710L/xx
Publication of SE9803710D0 publication Critical patent/SE9803710D0/xx
Priority to BR9913926-0A priority patent/BR9913926A/pt
Priority to AT99952857T priority patent/ATE362363T1/de
Priority to NZ510122A priority patent/NZ510122A/en
Priority to EP07009705.0A priority patent/EP1941872B1/en
Priority to EP10181344A priority patent/EP2324843A1/en
Priority to ES99952857T priority patent/ES2288319T3/es
Priority to US09/743,852 priority patent/US6649589B1/en
Priority to CA2714449A priority patent/CA2714449A1/en
Priority to HU0103839A priority patent/HUP0103839A3/hu
Priority to DE69936102T priority patent/DE69936102T2/de
Priority to CA2342200A priority patent/CA2342200C/en
Priority to EP99952857A priority patent/EP1115405B1/en
Priority to JP2000571927A priority patent/JP4832641B2/ja
Priority to RU2001111322/15A priority patent/RU2234336C2/ru
Priority to CN99813548A priority patent/CN1326351A/zh
Priority to PL99347469A priority patent/PL347469A1/xx
Priority to AU64918/99A priority patent/AU772036B2/en
Priority to PCT/SE1999/001671 priority patent/WO2000018409A1/en
Priority to CZ2001983A priority patent/CZ2001983A3/cs
Publication of SE9803710L publication Critical patent/SE9803710L/xx
Priority to US09/760,811 priority patent/US20010027175A1/en
Priority to US09/760,810 priority patent/US6635250B2/en
Priority to US09/826,893 priority patent/US20010055594A1/en
Priority to US10/225,237 priority patent/US7115557B2/en
Priority to US11/521,093 priority patent/US7708995B2/en
Priority to US11/648,957 priority patent/US7906481B2/en
Priority to US11/788,651 priority patent/US7811990B2/en
Priority to US12/102,178 priority patent/US7723357B2/en
Priority to US12/714,708 priority patent/US8057792B2/en
Priority to JP2010239148A priority patent/JP2011052001A/ja
Priority to JP2010258380A priority patent/JP2011063608A/ja
Priority to US13/295,309 priority patent/US20120093816A1/en
Priority to US13/489,830 priority patent/US20120244157A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
SE9803710A 1998-09-25 1998-10-29 Användning av vissa substanser för behandling av nervrotsskador SE9803710L (sv)

Priority Applications (33)

Application Number Priority Date Filing Date Title
SE9803710A SE9803710L (sv) 1998-09-25 1998-10-29 Användning av vissa substanser för behandling av nervrotsskador
AU64918/99A AU772036B2 (en) 1998-09-25 1999-09-23 Use of certain drugs for treating nerve root injury
CZ2001983A CZ2001983A3 (cs) 1998-09-25 1999-09-23 Pouľití léků inhibujících TNF-alfa pro léčení poranění nervového kořene
DE69936102T DE69936102T2 (de) 1998-09-25 1999-09-23 Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
RU2001111322/15A RU2234336C2 (ru) 1998-09-25 1999-09-23 Применение определенных лекарственных средств для лечения повреждения нервного корешка
PCT/SE1999/001671 WO2000018409A1 (en) 1998-09-25 1999-09-23 Use of certain drugs for treating nerve root injury
NZ510122A NZ510122A (en) 1998-09-25 1999-09-23 TNF-alpha in medicaments to treat symptoms of spinal disorders induced by nerve root injury such as sciatica and nucleus pulposus
EP07009705.0A EP1941872B1 (en) 1998-09-25 1999-09-23 Use of TNF-alpha inhibitors for treating nerve root injury
EP10181344A EP2324843A1 (en) 1998-09-25 1999-09-23 Use of TNF-alpha inhibitors for treating nerve root injury
ES99952857T ES2288319T3 (es) 1998-09-25 1999-09-23 Uso de un inhibidor tnt-alfa para el tratamiento de la lesion de las raices nerviosas.
US09/743,852 US6649589B1 (en) 1998-09-25 1999-09-23 Use of certain drugs for treating nerve root injury
CA2714449A CA2714449A1 (en) 1998-09-25 1999-09-23 Use of certain drugs for treating nerve root injury
HU0103839A HUP0103839A3 (en) 1998-09-25 1999-09-23 Use of certain drugs for treating nerve root injury
AT99952857T ATE362363T1 (de) 1998-09-25 1999-09-23 Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
CA2342200A CA2342200C (en) 1998-09-25 1999-09-23 Use of certain drugs for treating nerve root injury
EP99952857A EP1115405B1 (en) 1998-09-25 1999-09-23 Use of tnf-alpha inhibitors for treating nerve root injury
JP2000571927A JP4832641B2 (ja) 1998-09-25 1999-09-23 神経根障害を処置するための所定薬剤の使用
BR9913926-0A BR9913926A (pt) 1998-09-25 1999-09-23 Uso de um inibidor de tnf-alfa, e, processo para o tratamento dos distúrbios espinhais
CN99813548A CN1326351A (zh) 1998-09-25 1999-09-23 应用某些药物治疗神经根损伤
PL99347469A PL347469A1 (en) 1998-09-25 1999-09-23 Use of certain drugs for treating nerve root injury
US09/760,810 US6635250B2 (en) 1998-09-25 2001-01-17 Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
US09/760,811 US20010027175A1 (en) 1998-09-25 2001-01-17 Use of certain drugs for treating nerve root injury
US09/826,893 US20010055594A1 (en) 1998-09-25 2001-04-06 Use of certain drugs for treating nerve root injury
US10/225,237 US7115557B2 (en) 1998-09-25 2002-08-22 Use of certain drugs for treating nerve root injury
US11/521,093 US7708995B2 (en) 1998-09-25 2006-09-14 Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
US11/648,957 US7906481B2 (en) 1998-09-25 2007-01-03 Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
US11/788,651 US7811990B2 (en) 1998-09-25 2007-04-20 Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
US12/102,178 US7723357B2 (en) 1998-09-25 2008-04-14 Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus
US12/714,708 US8057792B2 (en) 1998-09-25 2010-03-01 Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
JP2010239148A JP2011052001A (ja) 1998-09-25 2010-10-25 神経根障害を処置するための所定薬剤の使用
JP2010258380A JP2011063608A (ja) 1998-09-25 2010-11-18 神経根損傷を治療するための所定薬剤の使用
US13/295,309 US20120093816A1 (en) 1998-09-25 2011-11-14 Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
US13/489,830 US20120244157A1 (en) 1998-09-25 2012-06-06 Use of tnf-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803276A SE9803276D0 (sv) 1998-09-25 1998-09-25 Use of certain drugs for treating nerve root injury
SE9803710A SE9803710L (sv) 1998-09-25 1998-10-29 Användning av vissa substanser för behandling av nervrotsskador

Publications (2)

Publication Number Publication Date
SE9803710D0 SE9803710D0 (sv) 1998-10-29
SE9803710L true SE9803710L (sv) 2000-03-26

Family

ID=26663404

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803710A SE9803710L (sv) 1998-09-25 1998-10-29 Användning av vissa substanser för behandling av nervrotsskador

Country Status (17)

Country Link
US (4) US6649589B1 (xx)
EP (3) EP1115405B1 (xx)
JP (3) JP4832641B2 (xx)
CN (1) CN1326351A (xx)
AT (1) ATE362363T1 (xx)
AU (1) AU772036B2 (xx)
BR (1) BR9913926A (xx)
CA (2) CA2342200C (xx)
CZ (1) CZ2001983A3 (xx)
DE (1) DE69936102T2 (xx)
ES (1) ES2288319T3 (xx)
HU (1) HUP0103839A3 (xx)
NZ (1) NZ510122A (xx)
PL (1) PL347469A1 (xx)
RU (1) RU2234336C2 (xx)
SE (1) SE9803710L (xx)
WO (1) WO2000018409A1 (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US7811990B2 (en) * 1998-09-25 2010-10-12 Sciaticon Ab Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
US7906481B2 (en) * 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
US6982089B2 (en) * 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
ES2278648T3 (es) * 1999-12-06 2007-08-16 Warsaw Orthopedic, Inc. Dispositivo para tratar un disco intervertebral.
TWI287987B (en) * 2000-08-14 2007-10-11 Senju Pharma Co Cytokine inhibitor
SE0101258D0 (sv) * 2001-04-06 2001-04-06 A & Science Invest Ab Treatment of low back pain and whiplash associated disorder
SE0101257D0 (sv) * 2001-04-06 2001-04-06 A & Science Invest Ab Treatment of whiplash associated disorder
SE0101256D0 (sv) * 2001-04-06 2001-04-06 A & Science Invest Ab Treatment of low back pain
EP2332550A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of neurodegenerative diseases
US20050277623A1 (en) * 2001-12-20 2005-12-15 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US20040054414A1 (en) * 2002-09-18 2004-03-18 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
CN100394989C (zh) 2002-11-15 2008-06-18 华沙整形外科股份有限公司 包含微粒状基于胶原材料的组合物的制药应用和包含所述组合物的滑膜关节
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
EP2286804A1 (en) * 2003-05-13 2011-02-23 DePuy Spine, Inc. A method of treating degenerative disc disease
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
AU2005302523A1 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
EP1933714B1 (en) 2005-09-21 2020-03-18 The Regents of The University of California Systems and compositions for local imaging and treatment of pain
US20080015465A1 (en) * 2006-06-15 2008-01-17 Scuderi Gaetano J Methods for diagnosing and treating pain in the spinal cord
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
US7879894B2 (en) 2006-11-28 2011-02-01 Warsaw Orthopedic, Inc. Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome
US7709215B2 (en) * 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US8883155B2 (en) * 2008-01-28 2014-11-11 The Regents Of The University Of California Methods for treating hematopoietic malignancies
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
US8653029B2 (en) 2009-07-30 2014-02-18 Warsaw Orthopedic, Inc. Flowable paste and putty bone void filler
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
CA2782320A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
US8475824B2 (en) * 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US8758791B2 (en) * 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US9886546B2 (en) 2012-11-20 2018-02-06 General Electric Company Methods and apparatus to label radiology images
RU2682257C2 (ru) * 2013-09-02 2019-03-18 Нестек С.А. Лактоферрин, улучшение памяти и повышение скорости обучения у детей
EA201790391A1 (ru) * 2014-08-15 2017-06-30 Пиксарбайо Корпорейшн Композиции для ингибирования воспаления у субъекта с повреждением спинного мозга и способы их применения
CA3234239A1 (en) * 2018-06-13 2019-12-19 Texas Tech University System Modified tetracycline for treatment of alcohol use disorder, pain and other disorders involving potential inflammatory processes

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707775A (en) * 1902-03-22 1902-08-26 Max Huncke Chemical Company Embalming-catheter.
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5686428A (en) 1989-04-07 1997-11-11 Aktiebolaget Astra Pharmaceutical composition
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JP2818056B2 (ja) 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
DE4028487A1 (de) 1990-09-09 1992-03-12 Peter Dr Med Wehling Entzuendung- und schmerzhemmendes nervenmittel
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE69218511T2 (de) 1991-07-10 1997-11-06 Nippon Steel Corp Kornorientiertes Siliziumstahlblech mit ausgezeichneten primären Glasfilmeigenschaften
US5763446A (en) 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
DE4219626A1 (de) 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
US20050260201A1 (en) 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
JP3312946B2 (ja) 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
US5807885A (en) 1993-08-12 1998-09-15 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
US5650396A (en) 1994-03-15 1997-07-22 Celtrix Pharmaceuticals, Inc. Methods of modulating inflammatory cytokines in the CNS using TGF-β
US5574022A (en) 1994-04-14 1996-11-12 The Center For Innovative Technology Method of attenuating physical damage to the spinal cord
US5703092A (en) 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US6001828A (en) 1995-06-05 1999-12-14 Andrulis, Jr.; Peter Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
BR9509297A (pt) 1995-08-10 1998-07-07 Astra Ab Composto composição farmacêutica utilização de um composto e processos de tratamento ou prolifaxia de uma doença ou condição na qual a síntese ou suprasintese da sintetase de óxido nitrico forma uma parte contribuinte e desordens neurodegenerativas ou de enxaqueca ou de prevenção e reversão da tolerância a opiatos e diazepinas ou de tratamento do vicio em tóxicos e de preparação de um composto
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
HN1997000027A (es) 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
BR9811093A (pt) 1997-02-10 2000-07-18 Pfizer Prod Inc Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
JP4733266B2 (ja) * 1997-12-19 2011-07-27 ニューヨーク ユニバーシティ シクロオキシゲナーゼ−２を阻害する方法および腫瘍壊死因子アルファ
AU752285B2 (en) 1998-05-07 2002-09-12 University Of Maryland At Baltimore A method for diagnosing and treating chronic pelvic pain syndrome
US20020132307A1 (en) 1998-08-12 2002-09-19 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20010055594A1 (en) 1998-09-25 2001-12-27 Kjell Olmarker Use of certain drugs for treating nerve root injury
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7906481B2 (en) 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
US6537549B2 (en) 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US20030007972A1 (en) 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US6419934B1 (en) 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6471961B1 (en) 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030113318A1 (en) 1999-02-24 2003-06-19 Tobinick Edward Lewis TNF inhibition for the treatment of pre-menstrual syndrome and primary dysmenorrhea
US20030185826A1 (en) 1999-02-24 2003-10-02 Tobinick Edward L. Cytokine antagonists for the treatment of localized disorders
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
US7214658B2 (en) 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US8119127B2 (en) 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
TW555812B (en) 1999-12-24 2003-10-01 Sumitomo Chemical Co Azo-compounds and dye polarizing films containing them
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
EP2241328A1 (en) 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
SE0200667D0 (sv) 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
US7226250B2 (en) 2003-12-22 2007-06-05 Hayes Lemmerz International, Inc. Tool and method for forming a lug hole
US20050220971A1 (en) 2004-04-01 2005-10-06 Katalin Coburn Process for making non-emulsified, spiced or flavored peanut butters and peanut butter spreads, with lower fat content, long shelf life, and minimal oil separation
TWI260774B (en) * 2005-07-19 2006-08-21 Quanta Display Inc Method for manufacturing liquid crystal display substrates

Also Published As

Publication number Publication date
US20080213283A1 (en) 2008-09-04
EP1941872A1 (en) 2008-07-09
ATE362363T1 (de) 2007-06-15
CN1326351A (zh) 2001-12-12
AU772036B2 (en) 2004-04-08
CA2342200A1 (en) 2000-04-06
CA2714449A1 (en) 2000-04-06
US20010027199A1 (en) 2001-10-04
JP2011063608A (ja) 2011-03-31
CZ2001983A3 (cs) 2002-02-13
JP4832641B2 (ja) 2011-12-07
JP2002525331A (ja) 2002-08-13
EP1115405B1 (en) 2007-05-16
ES2288319T3 (es) 2008-01-01
US7723357B2 (en) 2010-05-25
CA2342200C (en) 2010-11-23
US20010027175A1 (en) 2001-10-04
BR9913926A (pt) 2001-06-19
EP2324843A1 (en) 2011-05-25
PL347469A1 (en) 2002-04-08
US6635250B2 (en) 2003-10-21
SE9803710D0 (sv) 1998-10-29
JP2011052001A (ja) 2011-03-17
EP1941872B1 (en) 2013-04-10
AU6491899A (en) 2000-04-17
WO2000018409A1 (en) 2000-04-06
EP1115405A1 (en) 2001-07-18
HUP0103839A3 (en) 2004-06-28
DE69936102D1 (de) 2007-06-28
HUP0103839A2 (hu) 2002-02-28
DE69936102T2 (de) 2008-01-24
US6649589B1 (en) 2003-11-18
NZ510122A (en) 2003-05-30
RU2234336C2 (ru) 2004-08-20

Similar Documents

Publication Publication Date Title
SE9803710L (sv) Användning av vissa substanser för behandling av nervrotsskador
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
PL379983A1 (pl) Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
PT927161E (pt) Aminas ciclicas substituidas inibidoras de metaloproteases
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
AP2002002596A0 (en) Piperazine and piperidine derivatives.
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
ATE555787T1 (de) Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies
ITRM990707A0 (it) Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil l-carni
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE421326T1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
ATE355834T1 (de) Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9803710-4